tiprankstipranks
Trending News
More News >
Fine Foods & Pharmaceuticals N.T.M. SpA (IT:FF)
:FF
Italy Market
Advertisement

Fine Foods & Pharmaceuticals N.T.M. SpA (FF) AI Stock Analysis

Compare
6 Followers

Top Page

IT:FF

Fine Foods & Pharmaceuticals N.T.M. SpA

(FF)

Rating:73Outperform
Price Target:
€9.50
▲(9.45% Upside)
Fine Foods & Pharmaceuticals N.T.M. SpA demonstrates a strong technical position with bullish momentum, supported by reasonable valuation metrics. Financial performance shows recovery with improved profitability and leverage, but cash flow challenges remain a concern. The absence of earnings call and corporate events data limits further insights.
Positive Factors
Earnings
Adjusted net income reached EUR 9.7M, more than doubling year over year.
Financial Performance
Fine Foods delivered a solid performance, confirming the strength and resilience of its diversified business model.
Market Position
Fine Foods aims to gain market share and outperform peers by leveraging its scale, strong customer demand, and expanded capacity.
Negative Factors
Nutra Segment
A more cautious stance is warranted for the Nutra sector, as the nutraceutical segment is being redefined.
Revenue Decline
A relatively challenging year-over-year comparison and different order phasing led to a drop in group revenues.
Revenue Growth
The Nutra business unit is expected to have slower growth assumptions, leading to a slight reduction in group revenue.

Fine Foods & Pharmaceuticals N.T.M. SpA (FF) vs. iShares MSCI Italy ETF (EWI)

Fine Foods & Pharmaceuticals N.T.M. SpA Business Overview & Revenue Model

Company DescriptionFine Foods & Pharmaceuticals N.T.M. SpA (FF) is an Italian company that specializes in the contract development and manufacturing of products in the nutraceutical, pharmaceutical, and cosmetics sectors. The company offers a wide range of services including the formulation, production, and packaging of an array of products such as dietary supplements, over-the-counter pharmaceuticals, and beauty products. FF is known for its commitment to quality, innovation, and sustainable practices, providing tailored solutions to meet the specific needs of its clients.
How the Company Makes MoneyFine Foods & Pharmaceuticals N.T.M. SpA generates revenue through its contract development and manufacturing services. The company partners with various brands and companies, offering comprehensive services from product formulation to final packaging. Key revenue streams include manufacturing contracts for dietary supplements, pharmaceuticals, and cosmetics. The company's earnings are bolstered by its reputation for quality and innovation, which attracts long-term contracts with prominent clients. Additionally, FF may engage in strategic partnerships to expand its service offerings and enter new markets, further enhancing its revenue potential.

Fine Foods & Pharmaceuticals N.T.M. SpA Financial Statement Overview

Summary
Fine Foods & Pharmaceuticals N.T.M. SpA is showing signs of recovery with improved profitability and leverage metrics. The income statement reflects positive growth and margin improvements, while the balance sheet indicates better debt management. However, cash flow challenges persist, particularly with negative free cash flow, which could impact future investments and operational flexibility.
Income Statement
75
Positive
Fine Foods & Pharmaceuticals N.T.M. SpA has shown a consistent improvement in its gross profit margin, rising from 25.9% in 2022 to 38.9% in TTM 2025. The net profit margin has also improved to 3.9% in TTM 2025 from negative margins in previous years. Revenue growth is positive at 3.5% in TTM 2025, indicating a recovery from past declines. However, the EBIT and EBITDA margins, while improved, remain moderate, suggesting room for operational efficiency gains.
Balance Sheet
68
Positive
The company's debt-to-equity ratio has improved significantly from 0.90 in 2022 to 0.41 in TTM 2025, indicating better leverage management. Return on equity has also turned positive at 7.2% in TTM 2025, reflecting improved profitability. However, the equity ratio is not explicitly provided, and the company's total assets have decreased over the years, which could indicate potential risks in asset management.
Cash Flow
60
Neutral
Operating cash flow remains strong, but free cash flow has been negative in recent periods, with a significant decline in TTM 2025. The free cash flow to net income ratio is positive, but the negative free cash flow growth rate of -281.7% in TTM 2025 is concerning. This suggests potential challenges in generating cash from operations and managing capital expenditures effectively.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue249.65M243.75M251.81M206.85M194.42M173.03M
Gross Profit103.97M80.13M68.56M53.63M55.89M49.23M
EBITDA35.36M30.90M19.29M3.64M9.86M28.80M
Net Income12.44M8.16M-3.52M-9.50M-1.43M13.36M
Balance Sheet
Total Assets270.27M242.59M241.56M299.82M302.81M207.44M
Cash, Cash Equivalents and Short-Term Investments21.90M19.21M19.15M76.74M95.09M74.95M
Total Debt73.53M54.53M66.39M120.36M110.76M21.19M
Total Liabilities133.10M110.53M114.61M166.53M155.59M66.43M
Stockholders Equity137.16M132.06M126.95M133.29M147.22M141.01M
Cash Flow
Free Cash Flow-4.70M11.12M-329.75K-12.30M-21.75M14.66M
Operating Cash Flow36.90M45.85M18.54M3.69M-5.83M30.47M
Investing Cash Flow-38.31M-31.56M45.89M-15.31M-36.35M-12.34M
Financing Cash Flow8.11M-14.08M-55.66M4.74M55.95M-17.41M

Fine Foods & Pharmaceuticals N.T.M. SpA Technical Analysis

Technical Analysis Sentiment
Positive
Last Price8.68
Price Trends
50DMA
8.22
Positive
100DMA
7.80
Positive
200DMA
7.44
Positive
Market Momentum
MACD
0.15
Positive
RSI
57.41
Neutral
STOCH
47.79
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IT:FF, the sentiment is Positive. The current price of 8.68 is above the 20-day moving average (MA) of 8.63, above the 50-day MA of 8.22, and above the 200-day MA of 7.44, indicating a bullish trend. The MACD of 0.15 indicates Positive momentum. The RSI at 57.41 is Neutral, neither overbought nor oversold. The STOCH value of 47.79 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IT:FF.

Fine Foods & Pharmaceuticals N.T.M. SpA Peers Comparison

Overall Rating
UnderperformOutperform
Sector (63)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
73
Outperform
€212.16M17.07
1.62%1.00%376.92%
63
Neutral
$20.42B14.64-2.96%3.11%2.04%-6.12%
€125.08M13.429.43%
€69.42M16.83
€6.62M43.38
€207.04M9.17
€1.05B6.34
* Consumer Defensive Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IT:FF
Fine Foods & Pharmaceuticals N.T.M. SpA
8.64
0.50
6.14%
GB:0GEJ
Valsoia SpA
10.30
0.82
8.65%
IT:ENV
Enervit S.p.A.
4.00
0.93
30.29%
IT:HQF
High Quality Food SpA
0.59
-0.02
-3.28%
IT:IWB
Italian Wine Brands S.p.A.
22.10
1.36
6.56%
IT:NWL
NewPrinces S.p.A.
23.50
11.20
91.06%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 20, 2025